作为治疗急性白血病的药物,梅因抑制
Daniela V Wenge1, Scott A Armstrong1
1Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston MA.
Seminars in hematology
|September 12, 2025
概括
梅宁抑制剂对高HOXA基因表达的急性白血病,包括急性髓性白血病 (AML) 的治疗有前途. 抵抗机制正在研究,以改善组合疗法和扩大治疗选择.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 梅宁抑制剂向具有高HOXA基因表达特征的急性白血病.
- 这些白血病通常存在特定突变,如KMT2A重组和NPM1c突变,所有这些都依赖于KMT2A:Menin相互作用.
研究的目的:
- 审查Menin抑制剂的作用机制.
- 识别敏感疾病的子集,了解抵抗机制.
- 总结正在进行的临床试验和未来的治疗作用.
主要方法:
- 对急性白血病中Menin抑制剂的现有文献的综述.
- 临床试验数据和耐药性机制的分析.
- 讨论由Menin突变介导的遗传抵抗.
主要成果:
- 梅宁抑制剂在严重预治疗的急性髓性白血病 (AML) 中显示出有效性,Revumenib被FDA批准用于KMT2A重组的AML.
- 对单一疗法的耐药性是一个重大挑战,推动了对组合策略的研究.
- 目前正在进行的试验正在探索新诊断的AML和移植后维护中的Menin抑制剂.
结论:
- 门因抑制剂代表了针对特定急性白血病的向治疗的重大进展.
- 了解和克服耐药性对于最大化治疗效益至关重要.
- 组合疗法有可能改变大量AML患者的实践.
相关概念视频
Inhibition of Cdk Activity
5.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
597
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
597
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Enzyme Inhibition
91.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.6K


